Document is current
Any future updates will be listed below
-
Authors
Torres, Pascual
Rico-Rios, Santiago
Ceron-Codorniu, Miriam
Santacreu-Vilaseca, Marta
Seoane-Miraz, David
Jad, Yahya
Ayala, Victòria
Mariño, Guillermo
Beltran, Maria
Miralles, Maria P.
Andrés-Benito, Pol
Fernandez-Irigoyen, Joaquin
Santamaria, Enrique
López-Otín, Carlos
Soler, Rosa M.
Povedano, Monica
Ferrer, Isidro
Pamplona, Reinald
Wood, Matthew J. A.
Varela, Miguel A.
Portero-Otin, Manuel https://orcid.org/0000-0002-1823-0299
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI 20-00155, 23-00176)
Ministerio de Universidades (Programa Margarita Salas)
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (SGR)
Fundación Luzon (Ayuda Unzue)
Universitat de Lleida
- License Information
-
More Information
Article History
Received: 20 January 2024
Revised: 1 August 2024
Accepted: 2 August 2024
First Online: 21 September 2024
Declarations
:
: P.T., M.J.A.W., M.A.V., M.P.-O. are inventors in a patent application (2315883.5), priority request in UK covering the use of ASOs targeting ATG4B cryptic exon and multi-targets for TDP-43 proteinopathies.
